The company trying to put the needle out of business - by building a robotic pill that injects you from the inside, painlessly, and lets you swallow the shot you used to dread.
Somewhere in a clinic, a person who has spent years pinching skin and uncapping syringes is handed a glass of water and a capsule. No alcohol swab. No flinch. Inside that capsule is a small machine, and the machine is about to do the injecting - quietly, in the dark, where there are no nerves to complain.
Biologics - the peptides, proteins and antibodies behind modern medicine - are large, fragile molecules. The stomach treats them like lunch. For decades that left exactly one reliable route into the body: the needle. Rani Therapeutics looked at that constraint and decided it was a hardware problem, not a law of nature.
The answer is the RaniPill: a capsule engineered to ignore the stomach and wake up in the small intestine, where it performs a tiny, self-contained injection. The patient feels a pill. The drug behaves like a shot. That gap - between what the patient experiences and what the body receives - is the entire business.
Rani imagines a world without needles.
Four steps, no nerves, no pain. The intestinal wall has no sharp-pain receptors - which is the whole trick.
An enteric coating shields the capsule through stomach acid, keeping the biologic intact.
In the small intestine the higher pH dissolves the coating and triggers a chemical reaction.
A self-inflating balloon presses a dissolvable, drug-filled microneedle into the intestinal wall.
The richly vascularized wall absorbs the drug fast. No needle leaves the body - it dissolves.
That first figure is the one investors circle. A bioavailability at or above 100% means the swallowed capsule delivered the drug at least as efficiently as a syringe - the rare case where the more convenient option is not the weaker one.
The flagship robotic capsule for oral delivery of peptides, proteins and antibodies - the painless "injection from the inside."
A high-capacity variant built to carry larger payloads (20 mg or more), widening the menu of biologics that can be oralized.
A RaniPill carrying PG-102, a GLP-1/GLP-2 dual agonist licensed from ProGen, aimed at obesity. Phase 1 began January 2026.
Rani applies its delivery hardware to partners' injectable biologics under collaboration and licensing deals - notably Chugai.
Rani grew out of InCube Labs, the multidisciplinary incubator of serial medical inventor Mir Imran - a man with a long ledger of patents and a hand in early implantable cardiac defibrillator work. He spun Rani out in 2012 and remains Executive Chairman. In 2021 his son, Talat Imran, who had run strategy since 2014, took over as CEO.
Prolific medical inventor; founder of InCube Labs and the original architect of the RaniPill concept.
Former VP of Strategy; appointed CEO in 2021 to steer the company through clinical development and partnering.
Deep-tech medicine is patient capital. Rani has drawn backing from names that recognize a platform when they see one - GV (Alphabet), Novartis, AstraZeneca - before going public on Nasdaq in 2021.
FOOTNOTE. As of Q1 2026, Rani held $43.4M in cash with runway projected into Q4 2027, narrowed its net loss to $8.0M, and logged $1.7M in contract revenue - mostly from Chugai. Bar widths are illustrative, not to exact scale.
Rani spins out of Mir Imran's InCube Labs to chase oral delivery of biologics.
The "robotic" RaniPill capsule clears a first-in-human study, showing safe oral delivery.
IPO on Nasdaq under the ticker RANI.
Up to $1.085B collaboration with Chugai Pharmaceutical, plus an oversubscribed $60.3M financing.
Phase 1 of RT-114 begins with ProGen - a GLP-1/GLP-2 obesity biologic, delivered orally.
Q1 results: $43.4M cash, narrowed losses, CFO transition and new strategic advisors.
Return to that clinic. The capsule is gone now, swallowed minutes ago, already at work somewhere past the stomach. The person who used to flinch is checking their phone. If Rani is right, this is what a revolution in medicine looks like from the outside - which is to say, like nothing at all. No drama, no needle, no swab. Just someone taking a pill and getting on with the afternoon.
That is the quiet ambition of Rani Therapeutics: to make the most feared part of chronic treatment so boring it disappears. The science is still in trials, the stock is small, and the road from Phase 1 to pharmacy is long. But the picture they are selling is simple enough to draw on a napkin - and stubborn enough to have kept them at it for fourteen years.
The needle was never the medicine. It was just the delivery truck. Rani is trying to retire the truck.
Profile compiled from public sources. Figures approximate where noted. Not investment advice.